Independent GLP-1 & semaglutide coverage
Clear, sourced information on semaglutide and GLP-1 medications
Product comparisons, industry news, and regulatory tracking for Ozempic, Wegovy, Mounjaro, and the broader GLP-1 category — written for readers who want the sourcing, not the hype. Not a pharmacy. Not medical advice.
Product Reviews
Comparisons and device breakdowns for GLP-1 medications.

What Semaglutide Is: The GLP-1 Receptor Agonist Behind Ozempic, Wegovy and Rybelsus
Semaglutide is an engineered analogue of the gut hormone GLP-1, sold in the United States under several brand names. This profile covers what the molecule is, how it works, the major human trials, and what current FDA labels say about approved uses and risks.
6 min read
GHK-Cu and GLP-1 Drugs Are Both Peptides. That Is About Where the Similarity Ends
GHK-Cu and semaglutide are both called peptides, but they differ in size, origin, mechanism and regulatory standing. This explainer compares the copper tripeptide with the GLP-1 drug class using the peer-reviewed literature.
4 min read
Why GLP-1 Drug Labels Carry a Thyroid Tumor Warning, and What Human Studies Show
Every long-acting GLP-1 label in the U.S. opens with a boxed warning about thyroid C-cell tumors. Here's where that warning came from, why researchers think rodents and humans may differ, and what large observational studies have found so far.
5 min readNews & Insights
What's moving in the GLP-1 industry — pipeline, coverage, supply.

FDA Orders a Class-Wide GLP-1 Label Warning on a Rare Cause of Vision Loss
The FDA is requiring makers of all approved GLP-1 receptor agonists, including semaglutide and tirzepatide, to add a warning about a potential increased risk of NAION, a rare optic nerve condition. The agency said a causal link has not been established.
3 min read
A 503B Compounder Recalls Tirzepatide Vials Over Sterility Assurance
Apothecary Pharma, a North Carolina outsourcing facility, has recalled 22 vials of compounded tirzepatide nationwide, citing a lack of assurance of sterility. The FDA classified the recall as Class II.
3 min read
Verdiva Ends a Phase 2 Trial of Its Weekly GLP-1 Pill as a Maintenance Option
Verdiva Bio has terminated a Phase 2 study testing once-weekly oral ecnoglutide (VRB-101) for keeping weight off after injectable semaglutide or tirzepatide. The company cited a business decision, not safety, and says the drug remains in development.
3 min readPolicy & Regulation
How the US, EU, and China regulate GLP-1 medications.

The Medicare GLP-1 Bridge, Explained: Who Qualifies for the $50 Copay and How Long It Runs
Since July 1, 2026, a CMS demonstration has offered certain Part D enrollees Wegovy, Zepbound KwikPen, and Foundayo for weight management at a $50 monthly copay. CMS has extended it through December 31, 2027.
4 min read
How Generic GLP-1 Drugs Get Approved: The ANDA Pathway for Peptides
Generic liraglutide reached U.S. pharmacies through the abbreviated generic-drug pathway, not the biosimilar route. In July 2026 the FDA revised its draft recommendations for generic semaglutide and tirzepatide as well.
4 min read
The FDA's GLP-1 Ingredient 'Green List': How Import Alert 66-80 Works
Since September 2025, imported GLP-1 active ingredients can be detained at the U.S. border unless their manufacturer appears on an FDA green list, the reverse of the red-list approach many import alerts use.
4 min read